{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T15:40:02Z","timestamp":1745595602215,"version":"3.40.4"},"reference-count":10,"publisher":"BMJ","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ Case Reports"],"published-print":{"date-parts":[[2009]]},"abstract":"<jats:p>A man in his 40s with a past history of neutropenia during zonisamide administration developed agranulocytosis 1 month after adding on topiramate to treat intractable partial epilepsy. His concurrent medication included phenytoin and acetazolamide. His white blood cell count recovered 5 days after discontinuation of topiramate. Topiramate is a sulfamate whose mechanism of antiepileptic activity is considered to include inhibition of carbonic anhydrase. Topiramate has a potential risk for haematopoietic adverse events; such events are rare and are related to immuno-allergic reaction or toxic effect of sulfonamides and sulfamates, including carbonic anhydrase inhibitors. Because this class of drugs is commonly used as an anti-glaucoma or diuretic agent, particular attention should be paid when initiating topiramate to a patient with a history of sulfonamide or sulfamate induced agranulocytosis, or when co-administrating topiramate with sulfonamides and sulfamates including carbonic anhydrase inhibitors.<\/jats:p>","DOI":"10.1136\/bcr.11.2008.1273","type":"journal-article","created":{"date-parts":[[2009,6,5]],"date-time":"2009-06-05T07:27:43Z","timestamp":1244186863000},"page":"bcr1120081273","source":"Crossref","is-referenced-by-count":4,"title":["Topiramate induced agranulocytosis"],"prefix":"10.1136","volume":"2009","author":[{"given":"Eiko Nakano","family":"Minakawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2009,6,5]]},"reference":[{"key":"2025042508010792000_2009.jun05_1.bcr1120081273.1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767150-00008"},{"key":"2025042508010792000_2009.jun05_1.bcr1120081273.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1996.tb06029.x"},{"key":"2025042508010792000_2009.jun05_1.bcr1120081273.3","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-9-200705010-00009"},{"key":"2025042508010792000_2009.jun05_1.bcr1120081273.4","doi-asserted-by":"publisher","DOI":"10.1002\/med.20021"},{"key":"2025042508010792000_2009.jun05_1.bcr1120081273.5","doi-asserted-by":"publisher","DOI":"10.2174\/138161208783877956"},{"key":"2025042508010792000_2009.jun05_1.bcr1120081273.6","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJM196002042620508","article-title":"Fatal agranulocytosis associated with acetazolamide","volume":"262","author":"Hoffman","year":"1960","journal-title":"N Engl J Med"},{"key":"2025042508010792000_2009.jun05_1.bcr1120081273.7","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1992.01080160024004"},{"key":"2025042508010792000_2009.jun05_1.bcr1120081273.8","first-page":"123","article-title":"A case report of agranulocytosis due to zonisamide with the extremely high serum concentration of G-CSF","volume":"42","author":"Okajima","year":"1994","journal-title":"Clinical Pediatrics Sapporo"},{"key":"2025042508010792000_2009.jun05_1.bcr1120081273.9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0002-9394(14)74987-6","article-title":"Hematologic reactions to carbonic anhydrase inhibitors","volume":"100","author":"Fraunfelder","year":"1985","journal-title":"Am J Ophthalmol"},{"key":"2025042508010792000_2009.jun05_1.bcr1120081273.10","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e3282f15fb9"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr.11.2008.1273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T15:01:13Z","timestamp":1745593273000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr.11.2008.1273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009]]},"references-count":10,"alternative-id":["10.1136\/bcr.11.2008.1273"],"URL":"https:\/\/doi.org\/10.1136\/bcr.11.2008.1273","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2009]]}}}